Abstract Adrenoceptors beta-3-subtype mediate lipolysis and in the search for potential beta- 3-adrenergic receptors agonists for the treatment of obesity, we designed new arylethanolamines (structures 4, 5) and aryloxypropanolamines (structures 6, 7) derived from 2 (3H)-benzoxazolone and 2 (3H)-benzothiazolone.
